The long-running CRISPR–Cas9 patent dispute over rights to the lucrative gene-editing tool has taken a new turn with the European Patent Office announcing its intention to award Merck KGA…
VOLUME 35 NUMBER 9 SEPTEMBER 2017 NATURE BIOTECHNOLOGY
The long-running CRISPR–Cas9 patent dispute over rights to the lucrative gene-editing tool has taken a new turn with the European Patent Office announcing its intention to award Merck KGA…
VOLUME 35 NUMBER 9 SEPTEMBER 2017 NATURE BIOTECHNOLOGY